A cross-sectional descriptive study of breastfeeding behaviour and galactogogue use among private-sector patients in Cape Town, South Africa.
Galactogogues are often prescribed to augment breastmilk supply in resource-rich environments.  Galactogogues are dopamine antagonists such as antipsychotics, antiemetics and natural supplements which enhance lactation by increasing serum prolactin. Galactogogue-mediated rise in serum prolactin may transiently increase milk production, but after 2 weeks postpartum it has no effect on lactational performance. [5,7] A recent Cochrane review concluded that the use of galactogogues was not associated with a significant improvement in longer-term outcomes of breastfeeding in preterm infants.  In addition, galactogogues have safety concerns in the mother and the infant. The antipsychotics sulpiride and chlorpromazine cross into breastmilk, while chlorpromazine may adversely affect the developing central nervous system of the infant. [4,8] In turn, mothers may develop movement disorders such as acute dystonic reactions.  Antiemetics exploited for their blocking of dopamine receptors also have safety concerns.  Metoclopramide is structurally related to the antipsychotic sulpiride and not recommended during breastfeeding.  Domperidone has been associated with an increased risk of QT interval prolongation and sudden cardiac death.  Natural supplements such as milk thistle and fenugreek have limited safety data during lactation (DRUG-REAX Database, Truven Health Analytics, Inc).
Taken together, the exact extent of galactogogue use in SA is unknown and the awareness of the benefit-risk of galactogogue use by breastfeeding mothers has not been documented. The objectives of this study were to describe breastfeeding behaviour, assess galactogogue use and determine perceived efficacy and side-effects in breastfeeding mothers and their infants.
The investigators developed a questionnaire based on specific research gaps identified in the literature, followed by review from relevant experts in paediatrics, neonatology and breastfeeding consulting. The questionnaire contained three sections. The first section captured demographic information including factors previously shown to influence breastfeeding, such as type of delivery, parity and having skin-to-skin contact. It also assessed duration of breastfeeding, mixed feeding and reasons for not exclusively breastfeeding. The second section assessed galactogogue use, the type, duration, dose, who recommended it and what the perceived efficacy and duration of the effect were. The last section captured data regarding side-effects in the mother and infant (Table 1). According to the information gathered, participants were retrospectively classified into one of the following groups: exclusive breastfeeding, exclusive formula feeding, mixed feeding (breastfeeding and using formula milk concurrently), intermittent mixed feeding (exclusively breastfeeding, but who have used formula feeds in the past) and breastfeeding to formula feeding (mothers who are using only formula feeds, who in the past breastfed exclusively). The first day of data collection was used to pilot the questionnaire. No concerns were identified and the study commenced on the following day.
We approached the International Board Certified Lactation Consultants (IBCLCs) practising in the private sector in the Cape Town Metropole via the IBCLC's communication network. A total of 22 had been approached and 5 IBCLCs practising in Rondebosch, Bellville, Stellenbosch and Somerset West, agreed to participate in the study. All the mothers consulting the IBCLCs during an 8-week period (starting 6 October 2015) irrespective of the reason for the consultation, were asked to participate in the study by completing the questionnaire. The IBCLCs avoided data duplication by keeping a record of each participant who had completed a questionnaire.
Only data from participants who had signed informed consent and completed the questionnaire were included in the study. Questionnaires were excluded from the data set when, based on consensus by the researchers, answers were ambiguous or incomplete. Ethical approval was obtained from the Stellenbosch University Health Research Ethics Committee (ref. no. S15/04/093).
A total of 108 participants signed informed consent and completed the questionnaires. Data from four participants were excluded due to incomplete data.
Exclusive breastfeeding in this population was achieved by slightly more than 50% of the participants, with a downward trend with increasing age of the infant. The most common reason for the use of formula milk was insufficient breastmilk production in the opinion of the participant. A statistically significant association was found between galactogogue use and perceived insufficient breastmilk supply (p=0.013). There was no statistically significant association between type of delivery and exclusive breastfeeding (p=0.099). A statistically significant increase in exclusive breastfeeding rate was shown in mothers with two or more children (p=0.029), compared with mothers with only one child. Having skin-to-skin contact within 1 hour of delivery was not associated with an increase in exclusive breastfeeding in this study (p=0.308).
Galactogogues were used by more than half of the participants (54%, n=56). Counselling on breastfeeding techniques to enhance breastmilk production prior to using galactogogues was given to 64% (n=36) of galactogogue users. Non-prescription medication was used by 80% of galactogogue users; the berry elixir-containing 'Jungle Juice', for which there appeared to be no standard ingredients, was most widely used (52%, n=29) (Table 3). The dose and use of 'Jungle Juice' varied greatly between 250 mL and 2 L per day. Fenugreek was mostly used in the capsule form, at [less than or equal to] 3 capsules per day (90%, n=19). Prescription medication was used by 48% of galactogogue users, of which low-dose sulpiride (50 mg 2--3 times per day) was the most frequently used (Table 2). The median age of infants when starting sulpiride was 2 weeks, while the duration of sulpiride use was 4 weeks, with the interquartile range 2--11 weeks. A single galactogogue was used by almost half of the participants (46%, n=26), while two and three galactogogues (including both prescription medication and supplements) were simultaneously used in 21% (n=12) and 12.5% (n=7) of participants, respectively.
A subjectively judged good increase in milk production was reported by 41% (n=23) of the galactogogue users and 30% (n=17) of the group reported no effect. The majority of the users who no longer used a galactogogue reported that the effect lasted only during use (56%, n=18), or a few days after stopping (28%, n=9). No statistically significant associations were found between any of the medications used as galactogogues and the effect on breastmilk production, or the duration of the effect after stopping (Table 3).
Only a few participants reported that they were counselled on possible side-effects (21%, n=12) before galactogogue initiation. Side-effects were reported in 9 mothers and 2 infants. The side-effects were mostly associated with sulpiride, varying from improved emotional wellbeing (n=2) to moodiness (n=2), which was subjectively noted to be severe in one case. One participant also mentioned that sulpiride contributed to difficulty in losing weight. Other side-effects were associated with brewer's yeast (cramps in an infant and vaginal pruritis in a mother), berry elixir (improved maternal energy levels) and fenugreek (increased heart rate and breast congestion in one mother).
In most cases (55%, n=31), galactogogues were recommended by medical practitioners, with obstetricians accounting for 35% (n=20). Nursing practitioners and certified lactation practitioners recommended galactogogues in 38% (n=21) of cases. Forty-five percent (n=25) of galactogogue users reported a recommendation from friends, family or other sources.
Our study contributes to the limited SA data regarding breastfeeding behaviour, galactogogue use and perceived efficacy and side-effects in breastfeeding mothers and their infants. We found a high exclusive breastfeeding rate in all age categories compared with the national breastfeeding rates in SA,  which could be explained by the specific population group who were seeking the advice of breastfeeding consultants, indicating a high level of motivation to breastfeed.
Successful breastfeeding has been associated with vaginal delivery, skin-to-skin contact in the first hour after delivery and a higher parity. [9,10] In our study this association was found with parity, but not with the type of delivery or skin-to-skin contact. Reasons for this can be attributed to the study population who, while seeking breastfeeding advice and assistance, also commonly make use of private-sector healthcare, where there is a high incidence of caesarean delivery. It may, therefore, also imply a smaller than expected role for these factors in predicting breastfeeding success in a motivated population. We found that galactogogues were frequently prescribed and used by more than half of the participants, which is higher than in high-income settings internationally, where a 5--33% prevalence of galactagogue use has been documented. [11,12]
In our study, supplements were the most preferred galactogogues, with the use of fenugreek and berry elixir-containing juices being widespread, often in combination with prescription medications. Safety and efficacy data supporting the use of galactogogue supplements are limited. We found that the preferred prescription galactogogue was sulpiride. Internationally, domperidone is most frequently prescribed in high-income settings. 
Given the high incidence of galactogogue usage observed, it is noteworthy that a relatively high percentage of participants found no effect on breastmilk production when using galactogogues. This, along with the high motivation of this study group to breastfeed, might explain the high incidence of the use of a combination of galactogogues. Although an objective analysis of efficacy is limited by the retrospective study design, our data do not support this practice to improve breastfeeding performance.
Most participants used galactogogues for a number of weeks, and often when their infants were beyond the neonatal period. Galactogogues should be prescribed with care with the best scientific evidence available, taking into account that there is no evidence to support the use of a galactogogue for longer than 2 weeks,  and that after 2 weeks postpartum it has no proven effect on lactational performance. [5,7] In addition, infant suckling is the most important factor for breast milk production once lactation is established, and not prolactin-induced increases in breastmilk volume. 
We also assessed the subjective experience of potential side-effects. There are very limited data regarding the safety of galactogogues. The side-effects described by study participants were mostly minor complaints and some could be seen as positive effects. Of note is the relatively low rate of side-effects reported, especially in infants. The study design is such, however, that reliable conclusions cannot be drawn on the safety and potential risks of these medications.
Our study findings were limited by a number of factors, the first of which was the small sample size. Second, the study population was prone to selection bias, with only IBCLCs serving the private sector being included. It is likely that the clients attending these practices are highly motivated to breastfeed. While this allows the collection of data from those most likely to use galactogogues, it might skew the actual prevalence of galactogogue use in the general population. Thirdly, we cannot exclude reporting bias, given that the study was designed to investigate women who are highly motivated to breastfeed and, lastly, the study design was retrospective and uncontrolled.
Future research should prospectively collect galactogogue safety and efficacy data given the large proportion of women found in our study who use galactogogues for extended periods of time.
This study found that galactogogues were frequently used, with a prevalence that exceeded other published data. We found that sulpiride was frequently prescribed even though it was not recommended during breastfeeding. Furthermore, the time of initiation and duration of galactogogue use was not in accordance with current guidelines. Doctors and other healthcare practitioners should acknowledge breastfeeding mothers' concerns regarding insufficient milk supply, and place more emphasis on correct breastfeeding technique and other behavioural factors. 
Acknowledgements. The authors wish to thank the Undergraduate Research Incentive Fund at the Faculty of Medicine and Health Sciences, Stellenbosch University, as well as the participating IBCLCs practices in the Cape Town Metropolitan Area.
[1.] Donovan TJ, Buchanan K. Medications for increasing milk supply in mothers expressing breastmilk for their preterm hospitalised infants. Cochrane Database Syst Rev 2012;3:CD005544. https://doi.org/10.1002/14651858.cd005544
[2.] Horta B, Bahl R, Martines J, Victora C. Evidence on the Long-term Effects of Breastfeeding: Systematic Reviews and Meta-analysis. Geneva: World Health Organization, 2007.
[3.] World Health Organization. The WHO Global Data Bank on Infant and Young Child Feeding A--Z list. Geneva: WHO, 2010. http://www.who.int/nutrition/databases/infantfeeding/en (accessed 24 May 2015).
[4.] Zuppa AA, Sindico P, Orchi C, et al. Safety and efficacy of galactogogues: Substances that induce, maintain and increase breast milk production. J Pharm Pharm Sci 2010;13(2):162-174. https://doi org/10.18433/j3ds3r
[5.] Anderson PO. The galactogogue bandwagon. J Hum Lact 2013;29(1):7-10. https://doiorg/10.1177/0890334412469300
[6.] Anderson PO, Valdes V. A critical review of pharmaceutical galactagogues. Breastfeed Med 2007;2(4):229-242. https://doi.org/10.1089/bfm.2007.0013
[7.] Barguno J, Del Pozo E, Cruz M, Figueras J. Failure of maintained hyperprolactinemia to improve lactational performance in the late puerperium. J Clin Endocrinol Metab 1988;66(4):876-879. https://doi.org/10.1210/jcem-66-4-876
[8.] United States Committee on Drugs. American Academy of Pediatrics Committee on Drugs: Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776-789. https:// doi.org/10.1542/peds.108.3.776
[9.] Moore ER, Anderson GC, Bergman N, Dowswell T. Early skin-to-skin contact for mothers and their healthy newborn infants. Cochrane Database Syst Rev 2012;5(5):CD003519. https://doi org/10.1002/14651858.cd003519.pub3
[10.] Al-Sahab B, Lanes A, Feldman M, Tamim H. Prevalence and predictors of 6-month exclusive breastfeeding among Canadian women: A national survey. BMC Pediatr 2010;10(1):20. https://doi org/10.1186/1471-2431-10-20
[11.] Grzeskowiak LE, Lim SW, Thomas AE, Ritchie U, Gordon AL. Audit of domperidone use as a galactogogue at an Australian tertiary teaching hospital. J Hum Lact 2013;29(1):32-37. https://doi org/10.1177/0890334412459804
[12.] Mannion C, Mansell D. Breastfeeding self-efficacy and the use of prescription medication: A pilot study. Obstet Gynecol Int 2012;2012:1-8. https://doi.org/10.1155/2012/562704
[13.] Gabay MP. Galactogogues: Medications that induce lactation. J Hum Lact 2002;18(3):274-279. https://doi.org/10.1177/089033440201800311
N Steyn, (1) BOcc, MB ChB; M Zunza, (1) BComm (Applied Statistics), MSc (Clinical Epidemiology), PhD (Paediatrics); E H Decloedt, (2) MB ChB, BSc Pharmacol (Hons), MMed, FCCP (SA)
(1) Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa
(2) Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa
Corresponding author: E H Decloedt (email@example.com)
Table 1. Participant characteristics Characteristic Total number EBF, IMF, of participants, [dagger] [double n (%) * n (%) dagger] n (%) Participants included 104 58 (56) 9 (8) (N) Type of delivery Caesarean section 78 (75) 40 (69) 7 (78) Vaginal delivery 26 (25) 18 (31) 2 (22) 1 hour skin-to-skin 62 (60) 37 (64) 6 (67) contact post delivery Live children of participants 1 69 (66) 33 (57) 9(100) 2 29 (28) 22 (38) -- [greater than or 6 (6) 3 (5) -- equal to]3 Galactogogue use 56 (54) 26 (45) 7 (78) Breastfeeding advice received before galactogogue use 36 (64) 12 (46) 4 (44) Characteristic MF, BF-FF EFF, [section] [??] [parallel] n (%) n (%) n (%) Participants included 22 (21) 12 (12) 3 (3) (N) Type of delivery Caesarean section 22 (100) 6 (50) 3(100) Vaginal delivery -- 6 (50) -- 1 hour skin-to-skin 8 (36) 8 (67) 3(100) contact post delivery Live children of participants 1 17 (77) 8 (66) 2 (67) 2 4 (18) 2 (17) 1 (33) [greater than or 1 (5) 2 (17) -- equal to]3 Galactogogue use 16 (73) 7 (58) -- Breastfeeding advice received before galactogogue use 13 (81) 7 (100) N/A EBF = exclusive breastfeeding; IMF = intermittent mixed feeding; MF = mixed feeding; BF-FF = breastfeeding to formula feeding; EFF = exclusive formula feeding; N/A = not applicable. * Unless otherwise specified. [dagger] Mothers only breastfeeding and using no other milk supplement. [double dagger] Defined as mothers exclusively breastfeeding, but who have used formula feeds in the past. [section] Mothers breastfeeding and using formula supplementation concurrently. [??] Mothers who are using only formula feeds, who in the past breastfed exclusively. [parallel] Defined as mothers using formula feeds only. Table 2. Type of galactogogue used (N=56) Type N (%) EBF IMF MF BF-FF EFF Total 56 (54) 26 (46) 7 (13) 16 (29) 7(13) -- galactogogue use Prescription 27 (48) 7 (26) 3 (11) 10 (37) 7 (26) -- medication Sulpiride 25 (48) 7 (28) 3 (12) 9 (36) 6 (24) -- Metoclopramide 2 (4) 0 (0) 0 (0) 1 (50) 1 (50) -- Supplements 45 (80) Herbal 21 (47) 7 (33) 5 (24) 7 (33) 2 (10) -- (fenugreek) * Non-herbal 33 (73) 18 (55) 4 (12) 9 (27) 2 (6) -- (Jungle Juice [dagger] and Stoney [double dagger]) Miscellaneous 12 (27) 2 (17) 1 (8) 8 (67) 1 (8) -- [section] * Trigonella foenum-graecum is a herb containing phyto- oestrogens, which are plant chemicals similar to oestrogen. Diosgenin is specifically implicated to increase breastmilk production. [dagger] A tonic made with blackthorn berry elixir (50 mL), rehydration mixes (sachets containing carbohydrates, electrolytes and possibly antioxidants), fruit juice or rooibos tea (1 L) and water (2 L). Rescue remedy drops are sometimes added in varying quantities. [double dagger] A ginger-flavoured carbonated drink. [section] Other galactogogues include: Brewer's yeast--Saccharomyces cerevisiae Prolac--homeopathic combination sublingual tablet to stimulate milk production (Helonias ioica, Urtica urens, Ricinus communis, calcarea carbonica, calcarea phosphorica, Vitex agnus-castus, ferrum phosphoricum, Pulsatilla, graphites, calcarea fluorica) Lactogogue tea--herbal tea (can be made with the leaves of different herbal plants, although fenugreek is most commonly used) Lactation cookies--oats-based cookie containing brewer's yeast and flaxseed Protein powder--a powder containing one of three main proteins: whey, soy and casein Oats--Avena sativa Milk stout--stout containing lactose, often used in the fermentation of beer Table 3. Reasons for the use of formula milk (N=46) Reason n (%) Association of IMF MF BF-FF EFF reason listed and the use of a galactogogue (p-value) Perception of too 23 (50) 0.01 4 11 7 1 little breastmilk Mastitis, thrush 6 (13) 0.93 1 4 1 0 or painful breastfeeding Returned to work 2 (4) 0.29 0 2 0 0 and could not express Use of alcohol, 1 (2) 0.17 0 1 0 0 nicotine and other harmful substances Use of chronic 1 (2) 0.17 0 0 1 0 medication and recommended not to BF BF found to be 5 (11) 0.21 0 1 2 2 emotionally challenging Social pressures 0 0 0 0 0 0 to stop BF Infant refused to 10 (22) 0.25 0 3 7 0 take breastmilk Medical problems/ 17 (37) 0.22 5 9 2 1 medical advice to use formula milk Other 9 (20) 0.63 2 5 1 1
|Printer friendly Cite/link Email Feedback|
|Author:||Steyn, N.; Zunza, M.; Decloedt, E.H.|
|Publication:||South African Journal of Obstetrics and Gynaecology|
|Date:||May 1, 2017|
|Previous Article:||Preventive role of low-molecular-weight heparin in unexplained recurrent pregnancy loss.|
|Next Article:||Beliefs and practices in using misoprostol for induction of labour among obstetricians in Zimbabwe.|